Radiation triggering immune response and inflammation

Cancer Letters

Volumn 368, Issue 2, 2015, Pages 156-163

  Hekim, Nezih ^a   Cetin, Zafer ^a   Nikitaki, Zacharenia ^b   Cort, Aysegul ^a   Saygili, Eyup Ilker ^a  

^a SANKO UNIVERSITY   (Turkey)

^b NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

Author keywords

Danger signals; Immune response; Inflammation; Ionizing radiation; Low doses; Programmed cell death

Indexed keywords

CALRETICULIN; FAS ANTIGEN; FAS LIGAND; PROGRAMMED DEATH 1 LIGAND 1;

APOPTOSIS; CANCER RADIOTHERAPY; DENDRITIC CELL; DNA REPAIR; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; IONIZING RADIATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIOSENSITIVITY; SHORT SURVEY; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ANIMAL; CELL DEATH; CELL SURVIVAL; IMMUNE SYSTEM; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; RADIATION RESPONSE;

ANIMALS; CELL DEATH; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IMMUNE SYSTEM; INFLAMMATION; NEOPLASMS;

EID: 84941874108     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.04.016     Document Type: Review

References (94)

1. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin. Infect. Dis 2002, 34:1094-1097.
2. Pereira G.C., Traughber M., Muzic R.F. The role of imaging in radiation therapy planning: past, present, and future. Biomed Res. Int 2014, 2014:231090.
3. Ryan J.L. Ionizing radiation: the good, the bad, and the ugly. J. Invest. Dermatol 2012, 132:985-993.
4. Shao L., Luo Y., Zhou D. Hematopoietic stem cell injury induced by ionizing radiation. Antioxid. Redox Signal 2014, 20:1447-1462.
5. Merrick A., Errington F., Milward K., O'Donnell D., Harrington K., Bateman A., et al. Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naive T-cell priming. Br. J. Cancer 2005, 92:1450-1458.
6. Bortfeld T., Jeraj R. The physical basis and future of radiation therapy. Br. J. Radiol 2011, 84:485-498.
7. Hou D.L., Chen L., Liu B., Song L.N., Fang T. Identification of common gene networks responsive to radiotherapy in human cancer cells. Cancer Gene Ther 2014, 21:542-548.
8. Shokolenko I.N., Wilson G.L., Alexeyev M.F. Aging: a mitochondrial DNA perspective, critical analysis and an update. World J. Exp. Med 2014, 4:46-57.
9. Ishida T., Ishida M., Tashiro S., Yoshizumi M., Kihara Y. Role of DNA damage in cardiovascular disease. Circ. J. 2014, 78:42-50.
10. Hirokawa Y., Yasui W., Komaki-Cox R.U., Cox J.D., Itou K., Tahara E. Radiation therapy for cancer. The fifteenth anniversary of Hiroshima Cancer Seminar Foundation, the Seventeenth International Symposium of Hiroshima Cancer Seminar, November 2007. Cancer Sci 2008, 99:1287-1291.
11. Fritz T.E., Tolle D.V., Doyle D.E., Seed T.M., Cullen S.M. Hematologic responses of beagles exposed continuously to low doses of 60Co-gamma radiation. Experimental Hematology Today 1982, 229-240. Karger, Basel. S.J. Baum, G.D. Ledney, S. Thierfelder (Eds.).
12. Rodel F., Frey B., Gaipl U., Keilholz L., Fournier C., Manda K., et al. Modulation of inflammatory immune reactions by low-dose ionizing radiation: molecular mechanisms and clinical application. Curr. Med. Chem 2012, 19:1741-1750.
13. Fritz T.E., Seed T.M., Tolle D.V., Lombard L.S. Late effects of protracted whole body irradiation by 60Co gamma rays. Life-Span Radiation Effects Studies in Animals: What Can They Tell Us? 1986, 116-141. Office of Scientific and Technical Information United States Department of Energy, Washington, DC. R.C. Thompson, I.A. Mahaffey (Eds.).
14. Seed T.M., Meyers S.M. Chronic radiation-induced alteration in hematopoietic repair during preclinical phases of aplastic anemia and myeloproliferative disease: assessing unscheduled DNA synthesis responses. Cancer Res 1993, 53:4518-4527.
15. Testa N.G., Hendry J.H., Lajtha L.G. The response of mouse haemopoietic colony formers to acute or continuous gamma irradiation. Biomedicine 1973, 19:183-186.
16. Chu-Tse W., Lajtha L.G. Haemopoietic stem-cell kinetics during continuous irradiation. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med 1975, 27:41-50.
17. Gidali J., Bojtor I., Feher I. Kinetic basis for compensated hemopoiesis during continuous irradiation with low doses. Radiat. Res 1979, 77:285-291.
18. Baird M.C., Hendry J.H., Testa N.G. Radiosensitivity increases with differentiation status of murine hemopoietic progenitor cells selected using enriched marrow subpopulations and recombinant growth factors. Radiat. Res 1990, 123:292-298.
19. Lamerton L.F., Pontifex A.H., Blackett N.M., Adams K. Effects of protracted irradiation on the blood-forming organs of the rat. Part 1: continuous exposure. Br. J. Radiol 1960, 33:287-301.
20. Osipov A.N., Klokov D.Y., Elakov A.L., Rozanova O.M., Zaichkina S.I., Aptikaeva G.F., et al. Comparison in vivo study of genotoxic action of high- versus very low dose-rate gamma-irradiation. Nonlinearity Biol. Toxicol. Med 2004, 2:223-232.
21. Anderson R.E., Troup G.M. Effects of irradiation upon the response of murine spleen cells to mitogens. Am. J. Pathol 1982, 109:169-178.
22. James S.J., Makinodan T. T cell potentiation in normal and autoimmune-prone mice after extended exposure to low doses of ionizing radiation and/or caloric restriction. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med 1988, 53:137-152.
23. Makinodan T., James S.J. T cell potentiation by low dose ionizing radiation: possible mechanisms. Health Phys 1990, 59:29-34.
24. Liu C., Kimler B.F., Evans R.G., Morantz R.A. Immune adjuvants for chemotherapy or radiotherapy in the 9L rat brain tumor model. J. Neurooncol 1993, 15:113-123.
25. Abou-El-Ardat K., Monsieurs P., Anastasov N., Atkinson M., Derradji H., De Meyer T., et al. Low dose irradiation of thyroid cells reveals a unique transcriptomic and epigenetic signature in RET/PTC-positive cells. Mutat. Res 2012, 731:27-40.
26. Liu S.Z. Radiation-induced change in lymphocyte proliferation and its neuroendocrine regulation: dose-response relationship and pathophysiological implications. Nonlinearity Biol. Toxicol. Med 2004, 2:233-243.
27. Roses R.E., Datta J., Czerniecki B.J. Radiation as immunomodulator: implications for dendritic cell-based immunotherapy. Radiat. Res 2014, 182:211-218.
28. Chun S.H., Park G.Y., Han Y.K., Kim S.D., Kim J.S., Lee C.G., et al. Effect of low dose radiation on differentiation of bone marrow cells into dendritic cells. Dose Response 2012, 11:374-384.
29. Reth M. Hydrogen peroxide as second messenger in lymphocyte activation. Nat. Immunol 2002, 3:1129-1134.
30. Varano Della Vergiliana J.F., Lansley S., Tan A.L., Creaney J., Lee Y.C., Stewart G.A. Mesothelial cells activate the plasma kallikrein-kinin system during pleural inflammation. Biol. Chem 2011, 392:633-642.
31. Lu D.Y., Leung Y.M., Huang S.M., Wong K.L. Bradykinin-induced cell migration and COX-2 production mediated by the bradykinin B1 receptor in glioma cells. J. Cell. Biochem 2010, 110:141-150.
32. Sharma M., Halligan B.D., Wakim B.T., Savin V.J., Cohen E.P., Moulder J.E. The urine proteome as a biomarker of radiation injury: submitted to proteomics - clinical applications special issue: "Renal and urinary proteomics (Thongboonkerd)". Proteomics Clin. Appl 2008, 2:1065-1086.
33. Wan S., Pestka S., Jubin R.G., Lyu Y.L., Tsai Y.C., Liu L.F. Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PLoS ONE 2012, 7:e32542.
34. Chiriva-Internati M., Grizzi F., Pinkston J., Morrow K.J., Cunha N.D., Frezza E.E., et al. Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell. Dev. Biol. Anim 2006, 42:89-95.
35. Lugade A.A., Sorensen E.W., Gerber S.A., Moran J.P., Frelinger J.G., Lord E.M. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J. Immunol 2008, 180:3132-3139.
36. Driessens G., Hoffmann P., Pouwels M., Zlotta A., Schulman C., Velu T., et al. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma. J. Immunother 2009, 32:140-144.
37. Blank C.U. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. Curr. Opin. Oncol 2014, 26:204-214.
38. Gameiro S.R., Jammeh M.L., Wattenberg M.M., Tsang K.Y., Ferrone S., Hodge J.W. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 2014, 5:403-416.
39. Baragano Raneros A., Suarez-Alvarez B., Lopez-Larrea C. Secretory pathways generating immunosuppressive NKG2D ligands: new targets for therapeutic intervention. Oncoimmunology 2014, 3:e28497.
40. Ogawa Y., Nishioka A., Hamada N., Terashima M., Inomata T., Yoshida S., et al. Expression of fas (CD95/APO-1) antigen induced by radiation therapy for diffuse B-cell lymphoma: immunohistochemical study. Clin. Cancer Res 1997, 3:2211-2216.
41. Dovedi S.J., Adlard A.L., Lipowska-Bhalla G., McKenna C., Jones S., Cheadle E.J., et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014, 74:5458-5468.
42. Obeid M., Panaretakis T., Joza N., Tufi R., Tesniere A., van Endert P., et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007, 14:1848-1850.
43. Yang J.Y., Xia W., Hu M.C. Ionizing radiation activates expression of FOXO3a, Fas ligand, and Bim, and induces cell apoptosis. Int. J. Oncol 2006, 29:643-648.
44. Teitz-Tennenbaum S., Li Q., Rynkiewicz S., Ito F., Davis M.A., McGinn C.J., et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res 2003, 63:8466-8475.
45. Reits E.A., Hodge J.W., Herberts C.A., Groothuis T.A., Chakraborty M., Wansley E.K., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med 2006, 203:1259-1271.
46. McBride W.H., Chiang C.S., Olson J.L., Wang C.C., Hong J.H., Pajonk F., et al. A sense of danger from radiation. Radiat. Res 2004, 162:1-19.
47. Blankenstein T., Qin Z. The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr. Opin. Immunol 2003, 15:148-154.
48. Georgakilas A.G. Bystander and non-targeted effects: a unifying model from ionizing radiation to cancer. Cancer Lett 2015, 356:3-4.
49. Georgakilas A.G., Redon C.E., Ferguson N.F., Kryston T.B., Parekh P., Dickey J.S., et al. Systemic DNA damage accumulation under in vivo tumor growth can be inhibited by the antioxidant tempol. Cancer Lett 2014, 353:248-257.
50. Hatzi V.I., Laskaratou D.A., Mavragani I.V., Nikitaki Z., Mangelis A., Panayiotidis M.I., et al. Non-targeted radiation effects in vivo: a critical glance of the future in radiobiology. Cancer Lett 2015, 356:34-42.
51. Ma Z.F., Huang J.R., Cui N.P., Wen M., Chen B.P., Li Z., et al. [Expressions of immunogenic molecules in low-dose radiotherapy-treated human renal clear cell carcinoma 786-0 cells]. Zhonghua Yi Xue Za Zhi 2013, 93:2385-2387.
52. Son C.H., Bae J.H., Shin D.Y., Lee H.R., Choi Y.J., Jo W.S., et al. 4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model. J. Immunother 2014, 37:1-7.
53. Cheng M.L., Fong L. Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr. Treat. Options Oncol 2014, 15:115-126.
54. La Greca M., Grasso G., Antonelli G., Russo A.E., Bartolotta S., Angelo A.D., et al. Neoadjuvant therapy for locally advanced melanoma: new strategies with targeted therapies. Onco. Targets Ther 2014, 7:1115-1121.
55. Schweizer M.T., Drake C.G. Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014, 33:641-655.
56. Hodge J.W., Guha C., Neefjes J., Gulley J.L. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) 2008, 22:1064-1070. discussion 1075, 1080-1061, 1084.
57. Kono K., Mimura K., Kiessling R. Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell Death Dis 2013, 4:e688.
58. Binder R.J., Vatner R., Srivastava P. The heat-shock protein receptors: some answers and more questions. Tissue Antigens 2004, 64:442-451.
59. Pasi F., Paolini A., Nano R., Di Liberto R., Capelli E. Effects of single or combined treatments with radiation and chemotherapy on survival and danger signals expression in glioblastoma cell lines. Biomed Res. Int 2014, 2014:453497.
60. Raghavan M., Wijeyesakere S.J., Peters L.R., Del Cid N. Calreticulin in the immune system: ins and outs. Trends Immunol 2013, 34:13-21.
61. de la Cruz-Merino L., Illescas-Vacas A., Grueso-Lopez A., Barco-Sanchez A., Miguez-Sanchez C. Radiation for awakening the dormant immune system, a promising challenge to be explored. Front. Immunol 2014, 5:102.
62. Tesniere A., Apetoh L., Ghiringhelli F., Joza N., Panaretakis T., Kepp O., et al. Immunogenic cancer cell death: a key-lock paradigm. Curr. Opin. Immunol 2008, 20:504-511.
63. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med 2007, 13:54-61.
64. Panaretakis T., Joza N., Modjtahedi N., Tesniere A., Vitale I., Durchschlag M., et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 2008, 15:1499-1509.
65. 2+ levels favors plasma membrane surface exposure of calreticulin. Cell Death Differ 2008, 15:274-282.
66. Stern-Ginossar N., Gur C., Biton M., Horwitz E., Elboim M., Stanietsky N., et al. Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat. Immunol 2008, 9:1065-1073.
67. Upshaw J.L., Leibson P.J. NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes. Semin. Immunol 2006, 18:167-175.
68. Friese M.A., Wischhusen J., Wick W., Weiler M., Eisele G., Steinle A., et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 2004, 64:7596-7603.
69. Eisele G., Wischhusen J., Mittelbronn M., Meyermann R., Waldhauer I., Steinle A., et al. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 2006, 129:2416-2425.
70. Crane C.A., Han S.J., Barry J.J., Ahn B.J., Lanier L.L., Parsa A.T. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro-Oncol 2010, 12:7-13.
71. Kim J.Y., Son Y.O., Park S.W., Bae J.H., Chung J.S., Kim H.H., et al. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp. Mol. Med 2006, 38:474-484.
72. Tesniere A., Panaretakis T., Kepp O., Apetoh L., Ghiringhelli F., Zitvogel L., et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008, 15:3-12.
73. Rosental B., Appel M.Y., Yossef R., Hadad U., Brusilovsky M., Porgador A. The effect of chemotherapy/radiotherapy on cancerous pattern recognition by NK cells. Curr. Med. Chem 2012, 19:1780-1791.
74. Skov S., Pedersen M.T., Andresen L., Straten P.T., Woetmann A., Odum N. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 2005, 65:11136-11145.
75. Satwani P., Bavishi S., Saha A., Zhao F., Ayello J., van de Ven C., et al. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity. Cytotherapy 2014.
76. Boldin M.P., Goncharov T.M., Goltsev Y.V., Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996, 85:803-815.
77. Muzio M., Chinnaiyan A.M., Kischkel F.C., O'Rourke K., Shevchenko A., Ni J., et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996, 85:817-827.
78. Cohen P.L., Eisenberg R.A. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol 1991, 9:243-269.
79. Owen-Schaub L., Chan H., Cusack J.C., Roth J., Hill L.L. Fas and Fas ligand interactions in malignant disease. Int. J. Oncol 2000, 17:5-12.
80. Belka C., Marini P., Budach W., Schulze-Osthoff K., Lang F., Gulbins E., et al. Radiation-induced apoptosis in human lymphocytes and lymphoma cells critically relies on the up-regulation of CD95/Fas/APO-1 ligand. Radiat. Res 1998, 149:588-595.
81. Fulda S., Scaffidi C., Pietsch T., Krammer P.H., Peter M.E., Debatin K.M. Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation-induced apoptosis of brain tumor cells. Cell Death Differ 1998, 5:884-893.
82. Albanese J., Dainiak N. Ionizing radiation alters Fas antigen ligand at the cell surface and on exfoliated plasma membrane-derived vesicles: implications for apoptosis and intercellular signaling. Radiat. Res 2000, 153:49-61.
83. Abdulkarim B., Sabri S., Deutsch E., Vaganay S., Marangoni E., Vainchenker W., et al. Radiation-induced expression of functional Fas ligand in EBV-positive human nasopharyngeal carcinoma cells. Int. J. Cancer 2000, 86:229-237.
84. Shinoura N., Yamamoto N., Asai A., Kirino T., Hamada H. Adenovirus-mediated transfer of Fas ligand gene augments radiation-induced apoptosis in U-373MG glioma cells. Jpn. J. Cancer Res 2000, 91:1044-1050.
85. Archibald D.J., Neff B.A., Voss S.G., Splinter P.L., Driscoll C.L., Link M.J., et al. B7-H1 expression in vestibular schwannomas. Otol. Neurotol 2010, 31:991-997.
86. Deng L., Liang H., Burnette B., Beckett M., Darga T., Weichselbaum R.R., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest 2014, 124:687-695.
87. Kyi C., Postow M.A. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett 2014, 588:368-376.
88. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med 2012, 366:2443-2454.
89. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med 2013, 369:134-144.
90. Zeng J., See A.P., Phallen J., Jackson C.M., Belcaid Z., Ruzevick J., et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys 2013, 86:343-349.
91. Ozono S. Nivolumab (Anti-PD-1 antibody; ONO-4538/BMS-936558) in renal cancer. Gan to Kagaku Ryoho 2014, 41:1077-1080.
92. Deeks E.D. Nivolumab: a review of its use in patients with malignant melanoma. Drugs 2014, 74:1233-1239.
93. Sundar R., Soong R., Cho B.C., Brahmer J.R., Soo R.A. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014, 85:101-109.
94. Makarova K.S., Aravind L., Wolf Y.I., Tatusov R.L., Minton K.W., Koonin E.V., et al. Genome of the extremely radiation-resistant bacterium Deinococcus radiodurans viewed from the perspective of comparative genomics. Microbiol. Mol. Biol. Rev 2001, 65:44-79.